Pediatrix Medical Group, Inc.

For the period ended Sep 30, 2026. Filed Oct 29, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Oct 29, 2026

MD$31.29-1.7%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 (Unaudited)

Consolidated Balance Sheets

(in thousands, except share data)

	September 30, 2026	December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents	$311,916	$375,241
Short-term investments	113,921	124,482
Accounts receivable, net	231,818	229,665
Prepaid expenses	8,985	12,606
Income taxes receivable	8,473	12,641
Other current assets	8,963	8,879
Total current assets	684,076	763,514
Property and equipment, net	37,239	39,180
Goodwill	1,268,248	1,260,732
Intangible assets, net	13,095	16,862
Operating and finance lease right-of-use assets	33,710	34,330
Deferred income tax assets	45,160	73,922
Other assets	57,892	58,156
Total assets	$2,139,420	$2,246,696
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$342,859	$419,530
Current portion of debt and finance lease liabilities, net	179,949	26,806
Current portion of operating lease liabilities	11,021	11,591
Income taxes payable	1,902	984
Total current liabilities	535,731	458,911
Long-term debt and finance lease liabilities, net	397,771	570,532
Long-term operating lease liabilities	23,261	25,686
Long-term professional liabilities	235,498	238,353
Deferred income tax liabilities	61,428	57,024
Other liabilities	36,116	30,336
Total liabilities	1,289,805	1,380,842
Commitments and contingencies
Shareholders’ equity:
Preferred stock; $.01 par value; 1,000,000 shares authorized; none issued	—	—
Common stock; $.01 par value; 200,000,000 shares authorized; 78,092,928 and 82,976,110 shares issued and outstanding, respectively	781	830
Additional paid-in capital	850,574	947,566
Accumulated other comprehensive (loss) income	(1,740)	610
Retained earnings (deficit)	—	(83,152)
Total shareholders’ equity	849,615	865,854
Total liabilities and shareholders’ equity	$2,139,420	$2,246,696

Consolidated Statements of Income and Comprehensive Income

(in thousands, except per share data)

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	2026	2025	2026	2025
Net revenue	$501,374	$492,875	$1,465,353	$1,420,078
Operating expenses:
Practice salaries and benefits	341,543	332,326	1,023,403	992,859
Practice supplies and other operating expenses	19,559	20,200	56,244	59,500
General and administrative expenses	62,701	60,793	184,258	175,111
Depreciation and amortization	6,243	5,551	18,144	16,196
Transformational and restructuring related expenses	6,118	5,954	19,515	16,393
Total operating expenses	436,164	424,824	1,301,564	1,260,059
Income from operations	65,210	68,051	163,789	160,019
Investment and other income	5,864	5,883	15,172	14,347
Net gain on investments in divested businesses	—	20,906	—	20,906
Interest expense	(8,127)	(8,941)	(24,564)	(27,225)
Equity in earnings of unconsolidated affiliate	2,045	1,879	3,439	2,790
Total non-operating (expenses) income	(218)	19,727	(5,953)	10,818
Income before income taxes	64,992	87,778	157,836	170,837
Income tax provision	(18,001)	(16,070)	(41,430)	(39,132)
Net income	$46,991	$71,708	$116,406	$131,705
Other comprehensive income, net of tax
Unrealized holding (loss) gain on investments, net of tax of $423, $101, $720, and $496	(1,354)	309	(2,350)	1,517
Total comprehensive income	$45,637	$72,017	$114,056	$133,222
Per common and common equivalent share data:
Net income:
Basic	$0.61	$0.85	$1.47	$1.56
Diluted	$0.59	$0.84	$1.43	$1.54
Weighted average common shares:
Basic	77,275	84,609	79,053	84,649
Diluted	79,729	85,613	81,260	85,559

Consolidated Statements of Shareholders’ Equity

(in thousands)

	Common Stock
Number of · AdditionalPaid-in · AccumulatedOtherComprehensive · Retained Earnings · TotalShareholders’
	Shares	Amount	Capital	Income (Loss)	(Deficit)	Equity
Balance at January 1, 2026	82,976	$830	$947,566	$610	$(83,152)	$865,854
Net income	—	—	—	—	29,572	29,572
Unrealized holding loss on investments, net of tax	—	—	—	(533)	—	(533)
Common stock issued under employee stock purchase plan	30	—	544	—	—	544
Issuance of restricted stock	223	2	(2)	—	—	—
Forfeitures of restricted stock	(77)	—	—	—	—	—
Stock-based compensation expense	—	—	4,661	—	—	4,661
Repurchased common stock	(1,091)	(11)	(21,440)	—	—	(21,451)
Excise tax on share repurchases	—	—	(71)	—	—	(71)
Balance at March 31, 2026	82,061	821	931,258	77	(53,580)	878,576
Net income	—	—	—	—	39,843	39,843
Unrealized holding loss on investments, net of tax	—	—	—	(463)	—	(463)
Common stock issued under employee stock purchase plan	61	1	1,069	—	—	1,070
Issuance of restricted stock	1,138	11	(11)	—	—	—
Forfeitures of restricted stock	(162)	(2)	2	—	—	—
Stock-based compensation expense	—	—	5,075	—	—	5,075
Repurchased common stock	(1,875)	(19)	(42,725)	—	—	(42,744)
Excise tax on share repurchases	—	—	(380)	—	—	(380)
Balance at June 30, 2026	81,223	812	894,288	(386)	(13,737)	880,977
Net income	—	—	—	—	46,991	46,991
Unrealized holding loss on investments, net of tax	—	—	—	(1,354)	—	(1,354)
Common stock issued under employee stock purchase plan	30	—	678	—	—	678
Issuance of restricted stock	4	—	—	—	—	—
Forfeitures of restricted stock	(44)	—	—	—	—	—
Stock-based compensation expense	—	—	6,195	—	—	6,195
Repurchased common stock	(3,120)	(31)	(49,757)	—	(33,254)	(83,042)
Excise tax on share repurchases	—	—	(830)	—	—	(830)
Balance at September 30, 2026	78,093	$781	$850,574	$(1,740)	$—	$849,615
Balance at January 1, 2025	85,866	$859	$1,013,690	$(1,071)	$(248,540)	$764,938
Net income	—	—	—	—	20,737	20,737
Unrealized holding gain on investments, net of tax	—	—	—	779	—	779
Common stock issued under employee stock purchase plan	60	—	662	—	—	662
Forfeitures of restricted stock	(7)	—	—	—	—	—
Stock-based compensation expense	—	—	3,641	—	—	3,641
Repurchased common stock	(109)	(1)	(1,568)	—	—	(1,569)
Balance at March 31, 2025	85,810	858	1,016,425	(292)	(227,803)	789,188
Net income	—	—	—	—	39,260	39,260
Unrealized holding gain on investments, net of tax	—	—	—	429	—	429
Common stock issued under employee stock purchase plan	96	1	1,175	—	—	1,176
Issuance of restricted stock	963	10	(10)	—	—	—
Stock-based compensation expense	—	—	3,909	—	—	3,909
Repurchased common stock	(15)	—	(209)	—	—	(209)
Balance at June 30, 2025	86,854	869	1,021,290	137	(188,543)	833,753
Net income	—	—	—	—	71,708	71,708
Unrealized holding gain on investments, net of tax	—	—	—	309	—	309
Common stock issued under employee stock purchase plan	58	—	700	—	—	700
Issuance of restricted stock	172	1	(1)	—	—	—
Forfeitures of restricted stock	(20)	—	—	—	—	—
Stock-based compensation expense	—	—	5,150	—	—	5,150
Repurchased common stock	(1,231)	(12)	(20,855)	—	—	(20,867)
Excise tax on share repurchases	—	—	(87)	—	—	(87)
Balance at September 30, 2025	85,833	$858	$1,006,197	$446	$(116,835)	$890,666

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.